<DOC>
	<DOCNO>NCT01395602</DOCNO>
	<brief_summary>The aim study determine efficacy cabergoline , long-acting dopamine receptor agonist , body weight blood glucose healthy obese adult . This randomized double-blind placebo control study . Twenty subject randomly assign either placebo cabergoline 16 week . The effect treatment body weight blood glucose insulin level compare treatment versus placebo arm .</brief_summary>
	<brief_title>Effect Cabergoline Weight Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>age 18 55 year BMI 30 40 diabetes , clinically significant medical condition , use medication effect blood glucose body weight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>